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Evaluation of the antiamnesic effects of Phyllanthus amarus in mice
HANUMANTHACHAR JOSHI, M. PHARM., PH.D, D.N.1,  MILIND PARLE, M. PHARM., PH.D.2
SUMMARY
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by a gradual decline in memory. Phyllanhus
amarus is commonly known as bhumi amla in India and is traditionally used since centuries in ayurveda medicine. The present
study was undertaken to investigate the effects of Phyllanhus amarus (PA) on cognitive functions and brain cholinesterase activity
in mice. Elevated plus maze and passive avoidance paradigm were employed to evaluate learning and memory parameters. Three
doses (50, 100 and 200 mg/kg, p.o.) of aqueous extract of PA were administered for 8 successive days to both young and aged mice.
PA (50, 100 and 200 mg/kg) produced a dose-dependent improvement in memory scores of young and older mice. PA also reversed
successfully the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.). Interestingly, brain acetyl
cholinesterase activity was also reduced. The underlying mechanism of action for the observed nootropic effect may be attributed
to pro-cholinergic activity exhibited by PA in the present study. Therefore, it would be worthwhile to explore the therapeutic
potential of PA in the management of patients with cognitive disorders.
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Evaluación de los efectos antiamnésicos de Phyllanthus amarus en ratones
RESUMEN
La enfermedad de Alzheimer es un desorden neuro-degenerativo progresivo  que se caracteriza por una disminución gradual
de la memoria. El Phyllanhus amarus (PA),  se conoce comúnmente como bhumi amla en la India, y tradicionalmente se ha usado
durante siglos en la medicina  ayurvédica con diversas indicaciones. Este estudio  se hizo para investigar los efectos del PA en
las funciones cognitivas y en la actividad de la colinesterasa cerebral. Se emplearon las pruebas de laberinto  complejo y el paradigma
de evitación pasiva  a fin de evaluar los parámetros de memoria y aprendizaje. Se administraron tres dosis (50, 100 y 200 mg/kg vía
oral) de extracto acuoso de PA durante 8 días sucesivos, tanto a ratones jóvenes como adultos.  El PA (50, 100 y 200 mg/kg) produjo
una mejoría que depende de la dosis en los puntajes de memoria en los ratones jóvenes y en los adultos. EL PA también revirtió
con éxito la amnesia inducida por escopolamina (0.4 mg/kg, i.p.) y diazepam (1 mg/kg, i.p.). Es  de interés anotar que asimismo
disminuyó la actividad de la acetil colinesterasa cerebral. El mecanismo de acción subyacente para el efecto nootrópico observado
se puede  atribuir a la actividad pro-colinesterasa demostrada en el presente estudio. Por tanto,  se justificaría explorar el potencial
terapéutico del PA en el manejo de pacientes con  desórdenes cognitivos.
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Phyllanthus amarus Linn. (PA) is an annual weed of
the family of the Euphorbiaceae commonly known as
bhumi amla in India and is traditionally used to treat flu,
dropsy, diabetes, and jaundice. It is also used to treat
hepatic and urolitic diseases and have diuretic, antiviral1,
anticancer2,3, hepatoprotective4, antioxidant anti-
inflammatory5 activity.  PA mainly contains phyllnathin
and hypophyllanthin as active ingredients6,7. The aqueous
extract of PA had been employed for treatment of nervous
debility, epilepsy, as medhya (intellect promoting) and in
vata disorders. In the present study, the potential of
antiamnesic effects of  PA was investigated.
Enhancement in the life-span of human beings in
developed and developing countries has resulted in
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proportionate increase in the number of patients suffering
from senile dementia. Alzheimer’s disease (AD) is said to
be the leading cause of dementia in elderly individuals. AD
individuals exhibit deterioration in mental functions rendering
them incapacitated to perform normal daily activities.
However, evidence shows that AD can also afflict young
individuals as early as 40 years of age8,9. AD patients
exhibit marked decline in cognitive functions and severe
behavioral abnormalities such as irritability, aphasia, apraxia,
agnosia and restlessness10,11. Neuritic plaques (consisting
of a core of b-amyloid aggregates covered by dead
neurons, microglia and apolipoprotein E) and neurofibri-
llary tangles are the major pathological lesions of an
Alzheimer brain12. Since the allopathic system of medicine
is yet to provide a radical cure for Alzheimer’s disease, it
is worthwhile to explore the utility of traditional medicines.
In the light of above, the present study was undertaken to
investigate the influence of PA  on memory of mice. The
effects of PA  on brain acetylcholinesterase activity were
also studied.
MATERIALS AND METHODS
Collection of the plant material. Leaves and stems of
PA  Linn. were collected from Dehradun, Uttaranchal and
were dried at 50°C. A voucher specimen of the plant was
identified by taxonomists at botanical survey of India,
Dehradun. The voucher specimen (HKJ/PA-23) has been
kept at Department of Pharmaceutical  Sciences, Guru
Jambheshwar University, Hisar, Haryana, India.
Preparation of aqueous extract. Powdered PA (500
g) was extracted twice overnight with 2000 ml of distilled
water at room temperature. The supernatant was collected
and evaporated to dryness at 50°C under reduced pressure.
The yield of the extract was 10.4% w/w.
Animals. All the experiments were carried out using
male, Swiss Albino mice procured from the disease-free
small animal house of CCS Haryana Agricultural University,
Hisar (Haryana), India. Young (3-4 months old) mice weighing
around 20 g and older (12-15 months old) mice weighing
around 35 g were used in the present study. The animals had
free access to food and water, and they were housed in a
natural (12h each) light-dark cycle. Food given to mice
consisted of wheat flour kneaded with water and mixed with
a small amount of refined vegetable oil. The animals were
acclimatized for at least 5 days to the laboratory conditions
before behavioral experiments. Experiments were carried
out between 0900 h and 1800 h. The experimental protocol
was approved by the Institutional Animal Ethics Committee
(IAEC) and the care of laboratory animals was taken as per
the guidelines of CPCSEA, Ministry of Forests and
Environment, Government of India.
Chemicals. The drugs used in this study were obtained
from following drug houses. Scopolamine hydrobromide
(Sigma-Aldrich, USA), diazepam injection (Calmpose®,
Ranbaxy, India), 5,5-dithiobis-2-nitrobenzoic acid (DTNB),
acetylcholine iodide, eserine salicylate, sodium dihydrogen
phosphate, disodium hydrogen phosphate (Hi-Media, In-
dia). Scopolamine hydrobromide and diazepam injection
were dissolved separately in normal saline and injected
i.p., volume of i.p. injection was 1 ml/100 g of mouse.
Experimental protocol. In the present investigation,
the mice were divided into 52 different groups comprising
of 6 animals each for investigations using various
interoceptive as well as exteroceptive memory models and
for biochemical estimations. PA (50, 100 and 200 mg/kg,
p.o.) was administered to young and older mice of different
groups. These mice were exposed to the training session
using elevated plus maze or passive avoidance apparatus
on 8th day after 90 min of the last dose. Retention
(memory) of the learned task was recorded after 24 hours
i.e., on 9th day. Amnesia was induced in separate groups
(interoceptive model) of young mice by scopolamine (0.4
mg/kg, i.p.) or diazepam (1 mg/kg, i.p.) on 8th day after 90
minutes of the last dose. Piracetam (200 mg/kg, i.p.), an
established nootropic agent was injected for eight days to
positive control group of animals. The whole brains were
collected after 9 days of administration of PA.
EXTEROCEPTIVE BEHAVIOR MODELS
Elevated plus-maze. Elevated plus-maze served as
the exteroceptive behavioral model to evaluate memory in
mice. The procedure, technique and end point for testing
memory was followed as per the parameters described by
the investigators working in the area of psycho-
pharmacology13,14. The elevated plus maze for mice
consisted of two open arms (16 cm x 5 cm) and two
covered arms (16 cm x 5 cm x 12 cm) extended from a
central platform (5 cm x 5 cm), and the maze was elevated
to a height of 25 cm from the floor15. On the first day (i.e.
8th day of drug treatment), each mouse was placed at the
end of an open arm, facing away from the central platform.
Transfer latency (TL) was defined as the time (in seconds)
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taken by the animal to move from the open arm into one of
the covered arms with all its four legs. TL was recorded
on the first day (training session) for each animal. The
mouse was allowed to explore the maze for another 2 min
and then returned to its home cage. Retention of this
learned-task (memory) was examined 24 h after the first
day trial (i.e. 9th day, 24h after last dose). Significant
reduction in TL value of retention indicated improvement
in memory.
Passive avoidance paradigm. Passive Avoidance
Behavior based on negative reinforcement was used to
examine the long-term memory16,17. The apparatus
consisted of a box (27 cm x 27 cm x 27 cm) having three
walls of wood and one wall of Plexiglass, featuring a grid
floor (made up of 3 mm stainless steel rods set 8 mm
apart), with a wooden platform (10 cm x 7 cm x 1.7 cm)
in the center of the grid floor. The box was illuminated with
a 15 W bulb during the experimental period. Electric shock
(20 V, A.C.) was delivered to the grid floor18. Training (i.e.
30th day of drug treatment) was carried out in two similar
sessions. Each mouse was gently placed on the wooden
platform set in the center of the grid floor. When the mouse
stepped-down placing all its paws on the grid floor, shocks
were delivered for 15 seconds and the step-down latency
(SDL) was recorded. SDL was defined as the time (in
seconds) taken by the mouse to step down from the
wooden platform to grid floor with all its paws on the grid
floor. Animals showing SDL in the range of 2-15 seconds
during the first test were used for the second session and
the retention test. The second-session was carried out 90
min after the first test. During second session, if the
animals stepped down before 60 seconds, electric shocks
were delivered once again for 15 seconds. During the
second test, animals were removed from shock free zone,
if they did not step down for a period of 60 seconds and
were subjected to retention test. Retention (memory) was
tested after 24 h (i.e. 9th day, 24h after last dose) in a
similar manner, except that the electric shocks were not
applied to the grid floor observing an upper cut-off time of
300 seconds19,20. Significant increase in SDL value indicated
improvement in memory.
BIOCHEMICAL ESTIMATIONS
Collection of brain samples. The animals were
sacrificed by cervical decapitation under light anesthesia
on the 8th day, 90 mins after administration of the last dose
of PA. Immediately after decapitation whole brain was
carefully removed from the skull. For preparation of brain
homogenate, the fresh whole brain was weighed and
transferred to a glass homogenizer and homogenized in an
ice bath after adding 10 volumes of 0.9% w/v sodium
chloride solution. The homogenate was centrifuged at
3000 rpm for 10 min and the resultant cloudy supernatant
liquid was used for estimation of brain acetylcholinesterase
activity.
Estimation of brain cholinesterase .  Brain
cholinesterase activity was measured by the method of
Ellman et al with a slight modification21,22. 0.5 ml of the
cloudy supernatant liquid was pipetted out into 25 ml
volumetric flask and dilution was made with a freshly
prepared DTNB (5.5-dithiobis-2-nitrobenzoic acid) solution
(10 mg DTNB in 100 ml of Sorenson phosphate buffer, pH
8.0). From the volumetric flask, two 4 ml portions were
pipetted out into two test tubes. Into one of the test tubes,
2 drops of eserine solution was added. 1 ml of substrate
solution (75 mg of acetylcholine iodide per 50 ml of distilled
water) was pipetted out into both the tubes and incubated
for 10 min at 30°C. The solution in the tube containing
eserine was used for zeroing the colorimeter. The resulting
yellow color is due to reduction of DTNB by certain
substances in the brain homogenate and due to non-
enzymatic hydrolysis of substrate. After having calibrated
the instrument, change in absorbance per min of the
sample was read at 420 nm23.
Statistical analysis. All the results were expressed as
mean ± standard error (SEM). Data were analyzed using
one-way ANOVA followed by Tukey-Kramer’s test. P-
values <0.01 were considered as statistically significant.
RESULTS
Effect on transfer latency using elevated plus-
maze. Transfer latency (TL) of second day (day 9th of
drug treatment) reflected retention of learned task or
memory. The young animals treated with PA (50, 100 and
200 mg/kg, p.o.) showed dose-dependent reduction in TL
of 9 th day, indicating significant improvement in memory,
when compared with control group. These concentrations
of PA (50, 100 and 200 mg/kg, p.o.) also produced
significant improvement in memory (p< 0.001) of older
mice (Figure 1). Scopolamine (0.4 mg/kg, i.p.) and diazepam
(1 ml/kg, i.p.) injected before training significantly increased
(p<0.01) the TL of 9 th day indicating impairment in memory
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(amnesia) The mice treated with PA (50, 100 and 200 mg/
kg, p.o.) for 9 successive days reversed successfully the
amnesia induced by both scopolamine and diazepam (Fi-
gure 2). Piracetam (used as the positive control) at the
dose of 200 mg/kg, i.p. improved memory (p<0.01) of both
young and older mice and reversed the amnesia induced by
scopolamine and diazepam as expected.
Effect on step-down latency using passive
avoidance paradigm. Step Down Latency (SDL) of
second day (9th day of drug treatment) reflected the long-
term memory of animals. Various concentrations of PA
(50, 100 and 200 mg/kg, p.o.) administered to young and
older mice for 9 days, showed dose-dependent increase in
SDL values as compared to respective control groups
(Figure 3). PA (50, 100 and 200 mg/kg, p.o.) administered
for 9 days reversed memory deficits due to ageing induced
amnesia, it also reversed scopolamine and diazepam induced
amnesia (Figure 4). The groups of mice, which were
treated with piracetam (200 mg/kg, i.p.) for seven
successive days showed improvement in memory of
young as well as older mice.
Effect on brain acetyl cholinesterase activity. PA
(50, 100 and 200 mg/kg, p.o.) showed a remarkable
reduction in brain cholinesterase activity in young and
older mice, as compared to respective control groups by
using Ellman’s kinetic colorimetric method (Figure 5). PA
(50, 100 and 200 mg/kg, p.o.) reduced cholinesterase
activity in young and older mice as expected.
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Figure 1. Effect of P. amarus (PA) on transfer latency of young and aged mice.
Piracetam (200 mg/kg, i.p.) was used as standard drug
Values are mean ± SEM (n=5), ANOVA followed by Tukey-Kramer test. * p<0.01 compared to control (young mice), a.  p<0.001 compared
to control (young mice),  b.  p<0.01 compared to control (aged mice), c.  p<0.001 compared to control (aged mice)
Learning
Memory
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Figure 2. Effect of P. amarus (PA) on TL in scopolamine and diazepam induced amnesia.
Piracetam (200 mg/kg, i.p.) was used as standard drug
Values are mean ± SEM (n=5), ANOVA followed by Tukey-Kramer test.  a.  p<0.01 compared to diazepam, b. p<0.001 compared to
diazepam, c. p<0.01 compared to scopolamine, d. p<0.001 compared to scopolamine
DISCUSSION
There has been a steady rise in the number of patients
suffering from Alzheimer’s disease (AD) all over the
world. AD is a genetically heterogeneous neuro-
degenerative disorder, which is slow in onset but relentless
in progress24. There are around 35 million patients suffering
from AD all over the world, out of which United States of
America alone has around 4.5 million patients25. Despite
the severity and high prevalence of this disease, allopathic
system of medicine is yet to provide a satisfactory antidote.
Therefore, neurobiologists all over the world are looking
for new directions and alternative strategies for managing
this disease of senior citizens. In India AD patents are
estimated to be less than 3.5 million26. These prevalence
figures however, point out that the numbers of patients
suffering from AD are considerably small in India when
compared to USA. Therefore, the authors were motivated
to explore the potential of certain nutrients from Indian
dishes responsible for this protection against AD. In the
present study, P. amarus administered for 8 days improved
the memory of mice as reflected by diminished TL and
enhanced SDL values as compared to control animals.
Furthermore, pretreatment with PA for 8 days protected
the animals from memory deficits produced by scopolamine
and diazepam. These findings suggest the possible
neuroprotective role for PA.
Acetylcholine is considered as the most important
neurotransmitter involved in the regulation of cognitive
functions. There is extensive evidence linking the central
cholinergic system to memory27-29. Cognitive dysfunction
has been shown to be associated with reduced cholinergic
transmission and the facilitation of central cholinergic
transmission with improved memory30. Selective loss of
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Figure 3. Effect of P. amarus (PA) on SDL of young and aged mice.
Piracetam (200 mg/kg, i.p.) was used as standard drug
Values are mean ± SEM (n=5), ANOVA followed by Tukey-Kramer test. * p<0.01 compared to control (young mice), a. p<0.001 compared
to control (young mice), b. p<0.01 compared to control (aged mice), c. p<0.001 compared to control (aged mice)
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Figure 4. Effect of P. amarus (PA) on SDL in scopolamine and diazepam induced amnesia.
Piracetam (200 mg/kg, i.p.) was used as standard drug.
Values are mean ± SEM (n=5), ANOVA followed by Tukey-Kramer test.  a.  p<0.01 compared to diazepam, b.  p<0.001 compared to
diazepam, c.  p<0.01 compared to scopolamine, d. p<0.001 compared to scopolamine
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cholinergic neurons and decrease in cholinacetyltransferase
activity was reported to be a characteristic feature of
senile dementia of the Alzheimer’s type31.  Other research
findings using Glycyrrhiza glabra, Myristica fragrance
and Zingiber officinale have displayed a link between
memory improving effect and cholinesterase inhibition32.
In the present study, the PA when administered for 9 days
to young and older mice showed significant reduction of
brain acetylcholinesterase activity thereby probably facili-
tating cholinergic transmission and improving memory of
animals.
In the present study,  it was observed that PA inhibited
brain acetylcholinesterase enzyme, thereby elevating
acetylcholine concentration in brain homogenate and
ultimately improved memory of both young and older mice.
Hence, a combination of neuroprotective, anticholinesterase
and nootropic effects exhibited by PA may all be eventually
responsible for the memory improving effect observed in
the present study. Therefore, it would be worthwhile to
explore the therapeutic potential of P. amarus in the
management of Alzheimer patients.
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